SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Björkholm M) "

Sökning: WFRF:(Björkholm M)

  • Resultat 1-10 av 50
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Gruber, A, et al. (författare)
  • A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
  • 2003
  • Ingår i: Leukemia research. - 0145-2126 .- 1873-5835. ; 27, s. 323-
  • Tidskriftsartikel (refereegranskat)abstract
    • The cyclosporine analog Valspodar (PSC 833, Novartis Pharma) is a strong inhibitor of the mdr1 gene product p-glycoprotein (pgp). A phase I/II study was conducted in order to evaluate if addition of Valspodar to treatment with daunorubicin and cytarabine, given to patients with primary refractory or relapsed acute myeloid leukemia, could increase the complete remission rate. Fifty-three patients were treated in cohorts of three to six patients. Twelve patients reached a complete remission in bone marrow, five of whom also normalized their peripheral blood values. Three patients experienced treatment-related deaths from pneumonia, liver failure and cerebral hemorrhage, respectively. It is concluded that Valspodar 10mg/kg per 24h in combination with daunorubicin 45mg/m2 for 3 days and cytarabine 1g/m2 twice daily for 4 days is tolerable in this heavily pre-treated group of patients. Due to the moderate treatment results, the phase II part of the study was ended prematurely. The modulation of only pgp did not give an obvious improvement of the treatment results in this group of patients. ⌐ 2002 Elsevier Science Ltd. All rights reserved.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Glimelius, Ingrid, et al. (författare)
  • Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009 - trends in cure proportions by clinical characteristics.
  • 2015
  • Ingår i: American Journal of Hematology. - : Wiley. - 0361-8609 .- 1096-8652. ; 90:12, s. 1128-1134
  • Tidskriftsartikel (refereegranskat)abstract
    • Trends in Hodgkin lymphoma (HL) survival among patients treated outside of clinical trials provide real-world benchmark estimates of prognosis and help identify patient subgroups for targeted trials. In a Swedish population-based cohort of 1947 HL patients diagnosed 1992-2009 at ages 18-59 years, we estimated relative survival (RS), cure proportions (CP) and median survival times using flexible parametric cure models. Overall, the CP was 89% (95%CI:0.87-0.91) and median survival of the uncured was 4.6 years (95%CI:3.0-6.3). For patients aged 18-50 years diagnosed after the year 2000, CP was high and stable, whereas for patients 50-59 years cure was not reached. The survival of relapse-free patients was similar to that of the general population (RS5-year :0.99; 95%CI:0.98-0.99, RS15-year :0.95; 95%CI:0.92-0.97). The excess mortality of relapsing patients was 19 times (95%CI:12-31) that of relapse-free patients. Despite modern treatments, patients with adverse prognostic factors (e.g., advanced stage) still had markedly worse outcomes [CPstage:IIIB 0.82 (95%CI:0.73-0.89); CPstage:IVB 0.72, (95%CI:0.60-0.81)] and patients with international prognostic score (IPS) ≥3 had 2.7 times higher excess mortality (95%CI:1.0-7.0, p=0.04) than patients with IPS <3. High-risk patients selected for 6-8 courses of BEACOPP (bleomycin, etoposide, doxorubicin, cyclofosphamide, vincristine, procarbazine, prednisone)-chemotherapy had a 15-year relative survival of 87%, (95%CI:0.80-0.92), whereas the corresponding estimate for patients selected for 6-8 courses of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) was 93% (95%CI:0.88-0.97). These population-based results indicate limited fatal side-effects in the 15-year perspective with contemporary treatments, while the unmet need of effective relapse treatment remains of concern. BEACOPP-chemotherapy was still not sufficient in high-risk HL patients. This article is protected by copyright. All rights reserved.
  •  
10.
  • Gunnarsson, Niklas, et al. (författare)
  • Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia
  • 2016
  • Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 30:7, s. 1562-1567
  • Tidskriftsartikel (refereegranskat)abstract
    • We recently reported an increased incidence of second malignancies in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI). To elucidate whether this increase may be linked, not to TKI but rather to a hereditary or acquired susceptibility to develop cancer, we estimated the prevalence of malignancies, autoimmune disease (AD) and chronic inflammatory disease (CID) in CML patients prior to their CML diagnosis. Nationwide population-based registers were used to identify patients diagnosed with CML in Sweden 2002-2012 and to estimate the prevalence of other malignancies, AD and CID prior to their CML diagnosis. For each patient with CML, five matched controls were selected from the general population. Conditional logistic regression was used to calculate odds ratios (OR). Nine hundred and eighty-four CML patients were assessed, representing more than 45 000 person-years of follow-up. Compared with matched controls, the prevalence of prior malignancies and AD was elevated in CML patients: OR 1.47 (95% confidence interval (CI) 1.20-1.82) and 1.55 (95% CI 1.21-1.98), respectively. No associations were detected between CML and previous CID. An increased prevalence of other malignancies and AD prior to the diagnosis of CML suggest that a hereditary or acquired predisposition to cancer and/or autoimmunity is involved in the pathogenesis of CML.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 50
Typ av publikation
tidskriftsartikel (49)
konferensbidrag (1)
Typ av innehåll
refereegranskat (48)
övrigt vetenskapligt/konstnärligt (2)
Författare/redaktör
Björkholm, M (26)
Björkholm, Magnus (10)
Turesson, Ingemar (5)
Andersson, Therese M ... (5)
Dickman, Paul W. (5)
Landgren, Ola (5)
visa fler...
Höglund, Martin (4)
Lambert, Paul C. (4)
Kristinsson, Sigurdu ... (4)
Konradsson-Geuken, Å ... (3)
Holm, G (3)
GRUBER, A (3)
Mellqvist, Ulf-Henri ... (3)
Wahlin, Anders (3)
Simonsson, B. (3)
Pfeiffer, Ruth M. (3)
Bower, Hannah (3)
Goldin, Lynn R. (3)
Stenke, L (3)
Jardemark, Kent (3)
Markevarn, B (3)
Björkholm, Carl (3)
Marcus, Monica M (3)
Lundberg, J. (2)
Engstrand, L (2)
Eloranta, Sandra (2)
Ekbom, A (2)
Tidefelt, U (2)
Bjorkholm, M (2)
Porwit-MacDonald, A (2)
Sundblad, A (2)
Wahlin, A (2)
Langius-Eklöf, Ann (2)
Holte, H (2)
Andersson, Siv G. E. (2)
Leval, A (2)
Eloranta, S (2)
Hagström, Erik (2)
Claesson, HE (2)
Kalin, M (2)
Dickman, PW (2)
Osby, E (2)
Celsing, F (2)
Jerkeman, M (2)
Gannedahl, A (2)
Cars, T (2)
Hellner, C (2)
Björkholm, B (2)
Malmerfelt, Anna (2)
Schilström, Björn (2)
visa färre...
Lärosäte
Karolinska Institutet (41)
Uppsala universitet (19)
Lunds universitet (8)
Umeå universitet (4)
Linköpings universitet (4)
Stockholms universitet (3)
visa fler...
Kungliga Tekniska Högskolan (2)
Örebro universitet (2)
Röda Korsets Högskola (2)
visa färre...
Språk
Engelska (50)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (18)
Naturvetenskap (6)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy